Related Experiment Video
Updated: Sep 1, 2025

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
Geranylgeranyl pyrophosphate depletion by statins compromises skeletal muscle insulin sensitivity
Lai Wang1, Zuguo Zheng1, Lijun Zhu1
1State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
Background:
Statins are widely prescribed cholesterol-lowering drugs but have been shown to increase the risk of type 2 diabetes mellitus. However, the molecular mechanisms underlying the diabetogenic effect of statins are still not fully understood.
Methods:
The effects of geranylgeranyl transferase I and II (GGTase I and II) inhibition on insulin-stimulated glucose uptake and GLUT4 translocation, and the dependence of these effects on insulin signalling were investigated in skeletal muscle cells. The protective effects of geranylgeranyl pyrophosphate (GGPP) and its precursor geranylgeraniol (GGOH) on simvastatin-induced insulin resistance were evaluated in vitro and in vivo. The effect of GGTase II inhibition in skeletal muscle on insulin sensitivity in vivo was confirmed by adeno-associated virus serotype 9 (AAV9)-mediated knockdown of the specific subunit of GGTase II, RABGGTA. The regulatory mechanisms of GGTase I on insulin signalling and GGTase II on insulin-stimulated GLUT4 translocation were investigated by knockdown of RhoA, TAZ, IRS1, geranylgeranylation site mutation of RhoA, RAB8A, and RAB13.
Results:
Both inhibition of GGTase I and II mimicked simvastatin-induced insulin resistance in skeletal muscle cells. GGPP and GGOH were able to prevent simvastatin-induced skeletal muscle insulin resistance in vitro and in vivo. GGTase I inhibition suppressed the phosphorylation of AKT (Ser473) (-51.3%, P < 0.01), while GGTase II inhibition had no effect on it. AAV9-mediated knockdown of RABGGTA in skeletal muscle impaired glucose disposal without disrupting insulin signalling in vivo (-46.2% for gastrocnemius glucose uptake, P < 0.001; -52.5% for tibialis anterior glucose uptake, P < 0.001; -17.8% for soleus glucose uptake, P < 0.05; -31.4% for extensor digitorum longus glucose uptake, P < 0.01). Inhibition of RhoA, TAZ, IRS1, or geranylgeranylation deficiency of RhoA attenuated the beneficial effect of GGPP on insulin signalling in skeletal muscle cells. Geranylgeranylation deficiency of RAB8A inhibited insulin-stimulated GLUT4 translocation and concomitant glucose uptake in skeletal muscle cells (-42.8% for GLUT4 translocation, P < 0.01; -50.6% for glucose uptake, P < 0.001).
Conclusions:
Geranylgeranyl pyrophosphate regulates glucose uptake via GGTase I-mediated insulin signalling-dependent way and GGTase II-mediated insulin signalling-independent way in skeletal muscle. Supplementation of GGPP/GGOH could be a potential therapeutic strategy for statin-induced insulin resistance.
Insights
Statins can increase type 2 diabetes risk by affecting glucose uptake in muscles. Geranylgeranyl pyrophosphate (GGPP) and geranylgeraniol (GGOH) show potential to prevent statin-induced insulin resistance.
Area of Science:
- Biochemistry
- Molecular Biology
- Endocrinology
Background:
- Statins, widely used cholesterol-lowering drugs, are linked to an increased risk of type 2 diabetes mellitus.
- The precise molecular mechanisms behind statin-induced diabetes remain incompletely understood.
Purpose of the Study:
- To investigate the role of geranylgeranyl transferase I and II (GGTase I and II) inhibition in insulin resistance.
- To explore the protective effects of geranylgeranyl pyrophosphate (GGPP) and geranylgeraniol (GGOH) against statin-induced insulin resistance.
Main Methods:
- Examined insulin-stimulated glucose uptake and GLUT4 translocation in skeletal muscle cells following GGTase I and II inhibition.
- Utilized in vitro and in vivo models to evaluate GGPP and GGOH's protective effects against simvastatin-induced insulin resistance.
- Employed adeno-associated virus serotype 9 (AAV9)-mediated knockdown of RABGGTA to confirm GGTase II inhibition effects in vivo.
- Investigated regulatory mechanisms by targeting RhoA, TAZ, IRS1, and geranylgeranylation sites.
Main Results:
- Inhibition of GGTase I and II replicated simvastatin-induced insulin resistance in skeletal muscle cells.
- GGPP and GGOH demonstrated efficacy in preventing simvastatin-induced insulin resistance both in vitro and in vivo.
- GGTase I inhibition reduced AKT phosphorylation, while GGTase II inhibition impaired glucose disposal independently of insulin signaling.
- Specific molecular targets like RhoA, TAZ, IRS1, RAB8A, and RAB13 were identified as crucial for these processes.
Conclusions:
- Geranylgeranyl pyrophosphate regulates skeletal muscle glucose uptake through both insulin signaling-dependent (GGTase I) and independent (GGTase II) pathways.
- GGPP/GGOH supplementation presents a potential therapeutic strategy for managing statin-induced insulin resistance.
More Related Videos
09:40Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
Published on: January 19, 2017
11:50Fiber Type and Subcellular-Specific Analysis of Lipid Droplet Content in Skeletal Muscle
Published on: June 8, 2022
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Dipeptidyl Peptidase 4 Inhibitors
Insulin: The Receptor and Signaling Pathways
Oral Hypoglycemic Agents: Biguanides and Glitazones
Skeletal Muscle Relaxants: Adverse Effects
Unlike...